Prostatic Intraepithelial Neoplasia (PIN)

Definition

Prostatic intraepithelial neoplasia (PIN) consists of architecturally benign prostatic acini or ducts lined by cytologically atypical cells. The architecture is preserved, but the cells lining the glands show nuclear and nucleolar abnormalities. PIN is subclassified into two grades:

Low-grade PIN (LGPIN)
High-grade PIN (HGPIN)

(Campbell-Walsh-Wein Urology, p. 4589)

Grading: LGPIN vs. HGPIN

The distinction between LGPIN and HGPIN rests on the prominence of the nucleoli - a subjective criterion. Because of this:

Pathologists cannot reproducibly distinguish LGPIN from benign prostate tissue
LGPIN on needle biopsy carries no greater cancer risk than a benign biopsy
Diagnostic reports should not comment on LGPIN - it has no clinical significance

HGPIN is the clinically relevant entity. The inter-observer threshold variability explains the wide reported incidence range (0-25%), with an average of 4-5% on biopsy.

HGPIN as a Precursor Lesion

Evidence supporting HGPIN as a precursor to prostate carcinoma:

HGPIN foci are larger and more numerous in prostates with cancer versus those without
Greater amounts of HGPIN correlate with more multifocal carcinomas
Shared biomarkers and molecular changes between HGPIN and carcinoma
Histologic evidence of glands "budding off" from HGPIN foci that resemble early carcinoma
About 20% of HGPIN lesions harbor the TMPRSS2:ERG fusion gene - a molecular abnormality found in ~50% of prostate cancers
GSTP1 DNA methylation is detectable in ~70% of PIN lesions (vs. >90% of frank carcinomas) but is absent in normal prostate tissue and BPH

HGPIN is specifically a precursor to peripheral zone, intermediate- to high-grade adenocarcinomas. Low-grade carcinomas of the transition zone are not closely related to HGPIN.

Histology

High-grade prostatic intraepithelial neoplasia

The hallmark is cytologically atypical cells (large nuclei, prominent nucleoli) lining architecturally benign glands. A key distinguishing feature from invasive carcinoma is the preservation of basal cells in HGPIN (though they may be patchy), whereas adenocarcinoma lacks basal cells entirely.

Clinical Significance and Management

Cancer Risk After HGPIN Diagnosis

Scenario	Risk of Cancer on Repeat Biopsy
Unifocal HGPIN on extended initial sampling	~20-30% (not significantly higher than after benign biopsy)
HGPIN on ≥2 cores	Similar risk to "atypical suspicious for carcinoma" (ASAP)

~80% of cancers detected on repeat biopsy after HGPIN are Gleason score 6 (Grade Group 1)
PSA levels, DRE, and TRUS findings do not reliably predict who will have cancer on repeat biopsy
PIN itself does not elevate serum PSA

Recommended Follow-up

Unifocal HGPIN on extended initial sampling: repeat biopsy within the first year is unnecessary in the absence of other clinical indicators of cancer
Multifocal HGPIN (≥2 cores): warrants follow-up with serum/urine tests, imaging, and in some cases repeat biopsy with increased sampling of the atypical site
HGPIN on TUR (TURP): significance is unclear; in elderly patients, often no further workup; in younger men, more aggressive workup may be warranted

PINATYP (PIN with Atypia)

When HGPIN shows outpouchings or tangential sections with adjacent small atypical glands, this is designated PINATYP. This is difficult to distinguish from PIN with associated infiltrating carcinoma and usually requires:

Immunohistochemistry for basal cell markers (p63, 34βE12/CK5/6, HMWCK)
Cancer is diagnosed only when a large cluster of entirely negative glands is identified

The cancer risk after PINATYP diagnosis is the same as an "atypical suspicious for carcinoma" (ASAP) diagnosis.

Intraductal Carcinoma of the Prostate (IDC-P) - Key Distinction

IDC-P must be distinguished from HGPIN. IDC-P shows architectural or cytologic atypia that clearly exceeds that of HGPIN. Important points:

IDC-P on biopsy is frequently associated with high-grade cancer and poor prognostic parameters at radical prostatectomy
IDC-P mostly represents intraductal spread of carcinoma within preexisting ducts (not a preinvasive condition)
Patients with IDC-P only on biopsy should be treated with definitive therapy (not active surveillance)
When IDC-P coexists with only Gleason 3+3=6, higher-grade unsampled cancer is likely present - active surveillance is not appropriate

Summary Table

Feature	LGPIN	HGPIN
Clinical significance	None	Precursor to PCa
Report on biopsy?	No	Yes
Cancer risk on repeat biopsy	Not elevated	20-30%
Nucleoli	Inconspicuous	Prominent
Basal cells	Present	Present (may be patchy)
Repeat biopsy needed?	No	Depends on extent

Sources: Campbell-Walsh-Wein Urology, 3-Volume Set, pp. 4589-4591; Smith and Tanagho's General Urology, 19th Ed.

This is a shared conversation. Sign in to Orris to start your own chat.